Abingworth tees up a unique, $105M co-development fund for PhIII deals

John Carroll

The international team at likes investing in co-development programs, backing two companies that specialize in taking on the risk and cost of Phase III in exchange for a piece of a precalculated, multi-year payout that can be earned for success. And now it has its first, standalone stocked with $ 105 million to invest in more such pacts.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS